These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 28744892)
21. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint. Schmidli H; Bretz F; Racine-Poon A Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875 [TBL] [Abstract][Full Text] [Related]
22. Optimal choice of the number of treatments to be included in a clinical trial. Stallard N; Posch M; Friede T; Koenig F; Brannath W Stat Med; 2009 Apr; 28(9):1321-38. PubMed ID: 19243083 [TBL] [Abstract][Full Text] [Related]
23. A comparison of methods for constructing confidence intervals after phase II/III clinical trials. Kimani PK; Todd S; Stallard N Biom J; 2014 Jan; 56(1):107-28. PubMed ID: 24173686 [TBL] [Abstract][Full Text] [Related]
24. A group-sequential design for clinical trials with treatment selection. Stallard N; Friede T Stat Med; 2008 Dec; 27(29):6209-27. PubMed ID: 18792085 [TBL] [Abstract][Full Text] [Related]
25. The Performance of Fixed-Horizon, Look-Ahead Procedures Compared to Backward Induction in Bayesian Adaptive-Randomization Decision-Theoretic Clinical Trial Design. Lipsky AM; Lewis RJ Int J Biostat; 2019 Feb; 15(1):. PubMed ID: 30726189 [TBL] [Abstract][Full Text] [Related]
27. Designs for phase II trials allowing for a trade-off between response and toxicity. Conaway MR; Petroni GR Biometrics; 1996 Dec; 52(4):1375-86. PubMed ID: 8962459 [TBL] [Abstract][Full Text] [Related]
28. A Bayesian-adaptive decision-theoretic approach can reduce the sample sizes for multiarm exercise oncology trials. Buffart LM; Bassi A; Stuiver MM; Aaronson NK; Sonke GS; Berkhof J; van de Ven PM J Clin Epidemiol; 2023 Jul; 159():190-198. PubMed ID: 37245703 [TBL] [Abstract][Full Text] [Related]
29. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes. Moatti M; Chevret S; Zohar S; Rosenberger WF Methods Inf Med; 2016; 55(1):4-13. PubMed ID: 26404511 [TBL] [Abstract][Full Text] [Related]
30. Adaptive group sequential design for phase II clinical trials: a Bayesian decision theoretic approach. Chen Y; Smith BJ Stat Med; 2009 Nov; 28(27):3347-62. PubMed ID: 19725024 [TBL] [Abstract][Full Text] [Related]
37. Meta-analysis of studies with bivariate binary outcomes: a marginal beta-binomial model approach. Chen Y; Hong C; Ning Y; Su X Stat Med; 2016 Jan; 35(1):21-40. PubMed ID: 26303591 [TBL] [Abstract][Full Text] [Related]
38. Decision-theoretic designs for pre-phase II screening trials in oncology. Stallard N; Thall PF Biometrics; 2001 Dec; 57(4):1089-95. PubMed ID: 11764248 [TBL] [Abstract][Full Text] [Related]
39. Decision-theoretic designs for phase II clinical trials allowing for competing studies. Stallard N Biometrics; 2003 Jun; 59(2):402-9. PubMed ID: 12926725 [TBL] [Abstract][Full Text] [Related]
40. A flexible multi-stage design for phase II oncology trials. Tan MT; Xiong X Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]